AntidiabeticsSUBCUTANEOUSStandard
HUMALOG KWIKPEN
INSULIN LISPRO RECOMBINANT
Standard Dose
200 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview HUMALOG KWIKPEN is listed in Drugs@FDA under application 205747 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN LISPRO RECOMBINANT Form and strength SOLUTION;SUBCUTANEOUS - 200 UNITS/ML Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2025-05-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview HUMALOG KWIKPEN is listed in Drugs@FDA under application 205747 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN LISPRO RECOMBINANT Form and strength SOLUTION;SUBCUTANEOUS - 200 UNITS/ML Sponsor ELI LILLY AND CO Submission history Latest submission status date: 2025-05-07 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.